

Research Article

TP73 G4C14-A4T14 polymorphism and cancer susceptibility: evidence from 36 case-control studies

Jialin Meng^{1,2,3}, Shuo Wang⁴, Meng Zhang^{1,2,3}, Song Fan^{1,2,3}, Li Zhang^{1,2,3} and  Chaozha Liang^{1,2,3}

¹Department of Urology, The First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, Anhui, China; ²Institute of Urology, Anhui Medical University, Hefei, Anhui, China; ³Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University, Hefei, Anhui, China; ⁴The First Clinical College of Anhui Medical University, Hefei, Anhui, China

Correspondence: Chaozha Liang (liang_chaozha@ahmu.edu.cn) or Li Zhang (lizhang@ahmu.edu.cn)



G4C14-A4T14 polymorphism of TP73 gene has been reported with a potential association in cancer risks through affected cell homeostasis; however the results were not consistent. We performed a comprehensive meta-analysis to explore the associations between G4C14-A4T14 polymorphism and cancer susceptibility. Extensive retrieve was performed in PubMed, EMBASE, Google Scholar, Web of Science, Wanfang database and CNKI database up to May 20, 2018. Odds ratios (ORs) and 95% confidence intervals (CIs) were conducted to evaluate the overall strength of the associations in five genetic models, as well as in subgroup analyses. Q-test, false-positive report probability analysis and trial sequential analysis, Egger's test and Begg's funnel plot were applied to evaluate the robustness of the results. *In silico* analysis was managed to demonstrate the relationship of TP73 expression correlated with cancer tissues. Finally, 36 case-control studies with a total of 9493 cancer cases and 13,157 healthy controls were enrolled into the meta-analysis. The pooled results present a significantly higher risk of G4C14-A4T14 polymorphism in all the five genetic models, as well as in the subgroups of Caucasian, cervical cancer, colorectal cancer, H-B subgroup and comfort to Hardy-Weinberg equilibrium subgroup. *In silico* analysis revealed that the expression of TP73 in cervical cancer tissue is higher than it in corresponding normal tissue, as well as in cervical cancer. All in all, TP73 G4C14-A4T14 polymorphism causes an upgrade cancer risk, especially in Caucasian population. G4C14-A4T14 polymorphism might be a potential biomarker for judging the tumorigenesis of cervical cancer and colorectal cancer.

Introduction

Cancer is a pivotal public health and leads to the second cause of death problem around the world. In 2018, there are almost 4700 new cancer diagnoses per day, as well as about 1700 cancer-related deaths in United States [1]. Breast cancer, lung cancer and colorectal cancer are the most three frequently cancer of female in United States, while prostate cancer occupied the first diagnosis cancer in male [1]. Attributed to the increasing population growth and aging, cancer has also been the leading cause of death around China. In 2015, there are about 12,000 newly diagnosed invasive cancer cases on average per day, while over 7500 cancer death [2]. In the past decades, biological scientists have reported that environmental factors, genetic mutations and the multiple interactions between them mainly affect the process of tumorigenesis, and the new research results are also on the road, such as epigenetic control [3-5].

Tumor protein P73 (TP73), also known as P53-like transcription factor, is a pivotal member of TP53 family, which affects cell proliferation, apoptosis and cell-cycle regulation [6-8]. Compared with frequently mutant TP53 gene, TP73 is rarely mutated [9]. p73 protein, the encoded product of TP73, is homologous with p53, 63% of p73 has the same amino acid sequence with p53, so it plays a critical role in normal cell homeostasis, while it can partially compensate the loss of p53 protein function [10,11].

Received: 22 August 2018
Revised: 26 October 2018

Accepted: 08 November 2018

Accepted Manuscript Online:
12 November 2018
Version of Record published:
14 December 2018

G4A (*rs2273953*) and *C14T* (*rs1801173*), the two single-nucleotide polymorphisms (SNPs) of *TP73* at positions 4 (G>A) and 14 (C>T), are incomplete linkage disequilibrium with each other, so we called it as *G4C14-A4T14*. *G4C14-A4T14* is located at the upstream of *TP73* promoter in exon 2, it could influence the expression of *TP73* through a stem-loop structure [12,13]. In recent years, *G4C14-A4T14* polymorphism of *TP73* was identified implicated in the tumorigenesis of a variety of cancer types, including breast cancer, colorectal cancer, lung cancer, cervical cancer, esophageal cancer and so on [14–17]. Nevertheless, data arising from these published case-control studies were not consistent. One single study may have no sufficient power to identify slight influences of these polymorphisms on cancer susceptibility. Therefore, we conducted a comprehensive meta-analysis to explore the association between *G4C14-A4T14* polymorphism and cancer susceptibility.

Materials and methods

Literature search and study selection criteria

We conducted a comprehensive literature search from PubMed, EMBASE, Google Scholar, Web of Science, Wanfang database and CNKI database (up to May 20, 2018). The keywords applied to literature retrieve are as follows: “*TP73* OR (Tumor Protein P73) OR (P53-Like Transcription Factor)” AND “cancer OR carcinoma OR tumor OR tumor OR neoplasm.” AND “SNP OR mutation OR variant OR polymorphism”. Furthermore, the references from eligible studies were manually checked for additional relevant literature. The titles and abstracts of identifying studies were examined to exclude obvious irrelevant records. The full-text of the remaining articles was further carefully inspected to determine whether to report the correlation of between *G4C14-A4T14* polymorphism and cancer susceptibility.

All the eligible studies should fulfill the following inclusion criteria: (1) case-control studies focus on the correlation between *G4C14-A4T14* polymorphism and cancer susceptibility; (2) genotype frequency of the cases and controls could be obtained directly or indirectly through calculation; and (3) articles in English or Chinese. On the contrary, studies would be removed if they were: (1) case-report, meta-analysis, systematic review or repetitive publication; (2) lack of genotype frequency data; and (3) publications conducted on animals or cell lines.

Data extraction

Two independent investigators separately extracted the relative data with any disagreement resolved by rechecking and discussion. For every eligible study, the following data were extracted: the name of the first author, the date of publication, ethnicity, sample size, genotyping methods, and genotype frequency of the cases and controls. In the subgroup analysis by race, the Caucasian population typically lived in Europe or America, and the Asian population typically lived in Asia.

Statistical methods

All the statistical calculation was conducted with STATA 12.0 software (Stata, College Station, Texas) in the present study. ORs with corresponding 95% CIs were performed to measure the strength of the relationship between *G4C14-A4T14* polymorphism and cancer susceptibility. Five common genetic models applied for assessing gene-disease associations are allele contrast model (GC vs. AT), homozygote comparison model (GC/GC vs. AT/AT), heterozygote comparison model (GC/AT vs. AT/AT), dominant comparison model (GC/GC+GC/AT vs. AT/AT) and recessive comparison model (GC/GC vs. GC/AT+AT/AT) (AT/AT, homozygotes for the common allele; GC/AT, heterozygotes; GC/GC, homozygotes for the rare allele). Stratified analyses were also calculated by ethnicity, cancer type and the source of control. In addition, we applied the chi-squared (χ^2)-based Q-test to calculate between-study heterogeneity [18]. $P<0.1$ was indicated as a substantial level of heterogeneity, and a random-effects model (the Der-Simonian and Laird method) was selected to pool the data [19]; or else, the fixed-effects model (the Mantel-Haenszel method) was adopted. Moreover, we also conducted the Begg's funnel plots and Egger's test to evaluate the publication bias [20,21]. Hardy-Weinberg equilibrium (HWE) of controls was calculated by the χ^2 test to compare the expected and actual genotype frequencies among the controls in each study. All the statistical tests in this meta-analysis were two-tailed, and P -values ≤ 0.05 were considered statistically significant.

False-positive report probability analysis and trial sequential analysis

We also use the false-positive report probability (FPRP) method to evaluate the results. 0.2 was set as an FPRP threshold and assigned a prior probability of 0.1 to detect the odds ratio (OR) of 0.67/1.50 (protective/risk effects). The significant result with the FPRP values less than 0.2 was considered as a worthy finding [22,23]. Trial sequential analysis (TSA) was conducted with the guideline of a former publication. We set a significance of 5% for type I error, as well as a 30% significance of type II error, to calculate the required sample size, and built the TSA monitoring boundaries.




Figure 1. Flowchart presenting the study selection procedure

In silico analysis of TP73 expression

In order to further explore the relationship between *TP73* expression and cancer, we used a newly developed interactive web server, GEPIA (<http://gepia.cancer-pku.cn/>), to see the difference between tumor tissue and normal tissue. GEPIA provided the mRNA sequencing expression data of tumors and normal samples from the TCGA and the GTEx projects [24].

Results

Study characteristics

As shown in Figure 1, we found 1740 potentially relevant studies from PubMed, EMBASE, Google Scholar, Web of Science, Wanfang database and CNKI database. After reviewing titles and abstracts, we excluded 1537 publications not investigating the association between *TP73 G4C14-A4T14* polymorphism and cancer risk. And then, full texts of remaining articles were evaluated. In the end, 36 case-control studies with a total of 9493 cancer cases and 13,157 healthy controls were enrolled into the meta-analysis [14–17,25–53]. The characteristics of these studies were showed in Table 1. Among these publications, there are 6 concerned about cervical cancer [17,34,40,50–52], 5 about lung cancer [16,29,33,35,38], 4 about colorectal cancer [28,37,46,47], 4 about esophageal cancer [14,27,28,39], 4 about gastric cancer [28,39,43,48], 3 about breast cancer [15,26,30], 3 about squamous cell carcinoma of the head and neck [32,41,45], as well as other 7 publications focus on Endometrial cancer [36], lymphoma [31], melanoma [42], nasopharyngeal carcinoma [53], neuroblastoma [25], ovarian cancer [44] and prostate cancer [49], respectively. As to the ethnicity, 14 studies were performed in Caucasians, while the other 22 studies were managed in Asian population. The characteristics of each case-control study, genotype frequencies and HWE examination results were presented in Table 1. Four case-control studies were not comforted to HWE [16,32,37,45], and we further conducted a sensitive analysis to validate the influence of the three studies on the integrated data. In order to evaluate the quality of each enrolled studies, we applied Newcastle-Ottawa Scale (NOS) [45] and fill the result in Table S1, the result of PRISMA2009 checklist was also listed to present our meta-analysis work (Table S2).

Quantitative synthesis

Table 2 listed the main results of current meta-analysis work of polymorphisms in *G4C14-A4T14* and risk of cancer. The pooled results of the 36 included studies had shown that *G4C14-A4T14* polymorphism conferred a significantly higher overall risk to cancer susceptibility in all the five genetic models, allelic contrast model (GC vs. AT: OR =

Table 1 Characteristics of the enrolled studies on *TP73 G4C14-A4T14* polymorphism and cancer

First author	Year	Ethnicity	Genotyping method	Source of control	Cancer type	HWE	Case PAA	Control				
								PAB	PBB	HAA	HAB	HBB
Romain et al.	1999	Caucasian	PCR	P-B	Neuroblastoma	Y	31	39	3	94	49	7
Ahomadegbe et al.	2000	Caucasian	PCR	H-B	Breast cancer	Y	36	22	1	27	7	0
Ryan et al.	2001	Caucasian	PCR	P-B	Esophageal cancer	Y	42	41	1	72	65	15
Hamajima et al.	2002	Asian	PCR-CTPP	H-B	Esophageal cancer	Y	67	29	6	133	98	10
Hamajima et al.	2002	Asian	PCR-CTPP	H-B	Gastric cancer	Y	84	51	9	133	98	10
Hamajima et al.	2002	Asian	PCR-CTPP	H-B	Colorectal cancer	Y	87	50	10	133	98	10
Hiraki et al.	2003	Asian	PCR-CTPP	H-B	Lung cancer	Y	109	68	12	130	95	10
Huang et al.	2003	Asian	PCR-CTPP	P-B	Breast cancer	Y	118	64	18	153	112	17
Hishida et al.	2004	Asian	PCR-CTPP	H-B	Lymphoma	Y	49	43	11	261	152	27
Li(a) et al.	2004	Caucasian	PCR-CTPP	H-B	SCCHN	N	399	271	38	773	387	69
Li(b) et al.	2004	Caucasian	PCR	P-B	Lung cancer	Y	593	394	67	721	365	53
Niwa(a) et al.	2004	Asian	PCR-CTPP	H-B	Cervical cancer	Y	57	52	3	270	150	22
Hu et al.	2005	Asian	PCR-SSCP	P-B	Lung cancer	Y	255	149	21	295	248	45
Niwa(b) et al.	2005	Asian	PCR	H-B	Endometrial cancer	Y	61	39	14	270	150	22
Pfeifer et al.	2005	Caucasian	PCR-RFLP	P-B	Colorectal cancer	N	113	54	12	159	96	5
Choi et al.	2006	Asian	PCR	P-B	Lung cancer	Y	320	221	41	338	212	32
Ge et al.	2006	Asian	PCR-RFLP	H-B	Gastric cancer	Y	146	99	14	391	210	29
Ge et al.	2006	Asian	PCR-RFLP	H-B	Esophageal cancer	Y	214	113	21	391	210	29
Zheng et al.	2006	Asian	PCR-RFLP	P-B	Cervical cancer	Y	58	22	2	77	19	4
Chen et al.	2008	Caucasian	PCR-RFLP	P-B	SCCHN	Y	195	111	20	214	115	20
Li(c) et al.	2008	Caucasian	PCR	H-B	Melanoma	Y	468	287	150	497	302	39
Zheng et al.	2008	Asian	PCR-CTPP	P-B	Cervical cancer	Y	71	28	2	77	19	4
Deo Feo et al.	2009	Caucasian	PCR	H-B	Gastric cancer	Y	84	22	8	214	71	10
Kang et al.	2009	Asian	PCR	P-B	Ovarian cancer	Y	164	74	19	151	92	14
Misra et al.	2009	Caucasian	PCR	H-B	SCCHN	N	112	176	15	186	124	9
Lee et al.	2010	Asian	PCR-CTPP	P-B	Colorectal cancer	Y	183	171	29	271	173	25
Shirai et al.	2010	Asian	PCR-CTPP	H-B	Gastric cancer	Y	220	142	26	239	156	24
Arfaoui et al.	2010	Caucasian	PCR	P-B	Colorectal cancer	Y	77	47	26	109	73	22
Mittal et al.	2011	Caucasian	PCR-RFLP	P-B	Prostate cancer	Y	121	56	0	192	66	7
Craveiro et al.	2012	Caucasian	PCR	P-B	Cervical cancer	Y	95	38	8	119	48	9
Sun et al.	2012	Asian	PCR-CTPP	P-B	Cervical cancer	Y	107	100	11	128	80	12
Umar et al.	2012	Caucasian	PCR	P-B	Esophageal cancer	Y	174	70	11	200	51	4
Zhou et al.	2012	Asian	MALDI-TOF	P-B	Breast cancer	Y	106	59	5	100	67	11
Zhang et al.	2014	Asian	PCR	P-B	Nasopharyngeal carcinoma	Y	163	116	14	247	120	13
Wang et al.	2014	Asian	PCR-CTPP	P-B	Lung cancer	N	101	59	8	102	68	25
Feng et al.	2017	Asian	PCR	H-B	Cervical cancer	Y	103	67	10	114	55	11

Abbreviations: H-B, hospital based; HWE, Hardy-Weinberg equilibrium; N, polymorphisms did not conform to HWE in the control group; P-B, population based; SCCHN, squamous cell carcinoma of the head and neck; Y, polymorphisms conformed to HWE in the control group.

1.139, 95% CI = 1.048–1.238, $P=0.002$), homozygote comparison model (GC/GC vs. AT/AT: OR = 1.320, 95% CI = 1.071–1.627, $P=0.009$), heterozygote comparison model (GC/AT vs. AT/AT: OR = 1.123, 95% CI = 1.012–1.245, $P=0.028$), dominant comparison model (GC/GC+GC/AT vs. AT/AT: OR = 1.152, 95% CI = 1.044–1.272, $P=0.005$) and recessive comparison model (GC/GC vs. GC/AT+AT/AT: OR = 1.273, 95% CI = 1.038–1.563, $P=0.021$) (Table 2 and Figure 2).

Stratification analysis by cancer type

After overall pooled analysis, we also conducted stratification analysis by cancer type, in order to obtain more precise result about the *G4C14-A4T14* polymorphism and cancer susceptibility. As shown in Table 2 and Figure 3, the subgroup analysis of six enrolled colorectal cancer related studies have shown that *G4C14-A4T14* polymorphism was related to an increased cancer risk in allelic contrast model (GC vs. AT: OR = 1.204, 95% CI = 1.044–1.389,

Table 2 Results of pooled analysis for *TP73 G4C14-A4T14* polymorphism and cancer susceptibility


Comparison	Subgroup	N	P _H	P _Z	Random	Fixed
B vs. A	Overall	36	<0.001	0.002*	1.139 (1.048–1.238)	1.170 (1.119–1.223)
	Caucasian	14	0.001	<0.001*	1.279 (1.131–1.446)	1.317 (1.232–1.407)
	Asian	22	<0.001	0.228	1.062 (0.963–1.172)	1.060 (0.998–1.126)
	Breast cancer	3	0.091	0.940	0.985 (0.666–1.457)	0.929 (0.747–1.156)
	Colorectal cancer	4	0.339	0.011*	1.197 (1.027–1.395)	1.204 (1.044–1.389)
	SCCHN	3	0.007	0.062	1.308 (0.987–1.733)	1.274 (1.134–1.432)
	Cervical cancer	6	0.982	0.031*	1.190 (1.016–1.393)	1.189 (1.016–1.392)
	Esophageal cancer	4	0.010	0.873	1.027 (0.738–1.430)	1.057 (0.903–1.236)
	Gastric cancer	4	0.739	0.261	1.084 (0.943–1.247)	1.084 (0.942–1.247)
	Lung cancer	5	<0.001	0.657	0.943 (0.726–1.224)	1.034 (0.945–1.132)
	P-B	20	<0.001	0.176	1.082 (0.965–1.213)	1.098 (1.033–1.168)
	H-B	16	<0.001	0.001*	1.213 (1.079–1.365)	1.256 (1.177–1.340)
	HWE(Y)	32	<0.001	0.003*	1.138 (1.044–1.239)	1.165 (1.109–1.222)
	HWE(N)	4	<0.001	0.484	1.132 (0.799–1.604)	1.200 (1.071–1.345)
BB vs. AA	Overall	36	<0.001	0.009*	1.320 (1.071–1.627)	1.420 (1.265–1.593)
	Caucasian	14	<0.001	0.011*	1.649 (1.119–2.431)	1.806 (1.523–2.142)
	Asian	22	0.033	0.151	1.170 (0.944–1.450)	1.152 (0.984–1.350)
	Breast cancer	3	0.189	0.952	0.918 (0.370–2.279)	0.983 (0.558–1.732)
	Colorectal cancer	4	0.676	0.001*	1.807 (1.258–2.595)	1.820 (1.270–2.608)
	SCCHN	3	0.136	0.196	1.336 (0.807–2.211)	1.235 (0.897–1.699)
	Cervical cancer	6	0.949	0.697	0.925 (0.590–1.451)	0.916 (0.587–1.428)
	Esophageal cancer	4	0.048	0.734	1.165 (0.484–2.804)	1.168 (0.762–1.79)
	Gastric cancer	4	0.815	0.114	1.351 (0.935–1.951)	1.345 (0.931–1.944)
	Lung cancer	5	0.001	0.748	0.912 (0.522–1.595)	1.039 (0.823–1.311)
	P-B	20	0.002	0.470	1.107 (0.841–1.457)	1.136 (0.968–1.335)
	H-B	16	0.001	0.001*	1.625 (1.210–2.183)	1.809 (1.532–2.136)
	HWE(Y)	32	<0.001	0.007*	1.342 (1.085–1.659)	1.476 (1.303–1.671)
	HWE(N)	4	0.001	0.579	1.288 (0.526–3.152)	1.117 (0.819–1.524)
BA vs. AA	Overall	36	<0.001	0.028*	1.123 (1.012–1.245)	1.133 (1.070–1.200)
	Caucasian	14	<0.001	0.008*	1.252 (1.061–1.477)	1.251 (1.149–1.362)
	Asian	22	<0.001	0.458	1.049 (0.924–1.191)	1.044 (0.966–1.129)
	Breast cancer	3	0.100	0.284	0.941 (0.587–1.510)	0.859 (0.651–1.134)
	Colorectal cancer	4	0.026	0.901	0.978 (0.693–1.381)	1.059 (0.879–1.276)
	SCCHN	3	0.002	0.051	1.494 (0.998–2.236)	1.446 (1.246–1.678)
	Cervical cancer	6	0.748	0.001*	1.414 (1.159–1.725)	1.413 (1.159–1.722)
	Esophageal cancer	4	0.031	0.953	1.011 (0.702–1.457)	1.023 (0.841–1.244)
	Gastric cancer	4	0.295	0.867	1.007 (0.821–1.234)	1.015 (0.849–1.214)
	Lung cancer	5	0.002	0.781	0.964 (0.742–1.251)	1.044 (0.929–1.172)
	P-B	20	<0.001	0.129	1.113 (0.969–1.279)	1.118 (1.033–1.209)
	H-B	16	<0.001	0.129	1.134 (0.964–1.334)	1.152 (1.059–1.253)
	HWE(Y)	32	<0.001	0.065	1.101 (0.994–1.219)	1.098 (1.032–1.169)
	HWE(N)	4	<0.001	0.325	1.245 (0.805–1.927)	1.348 (1.165–1.560)
BB+BA vs. AA	Overall	36	<0.001	0.005*	1.152 (1.044–1.272)	1.174 (1.111–1.240)
	Caucasian	14	0.004	<0.001*	1.312 (1.140–1.511)	1.327 (1.224–1.440)
	Asian	22	<0.001	0.332	1.063 (0.940–1.203)	1.059 (0.984–1.141)
	Breast cancer	3	0.096	0.860	0.959 (0.605–1.520)	0.880 (0.675–1.148)
	Colorectal cancer	4	0.073	0.538	1.092 (0.824–1.447)	1.151 (0.964–1.375)
	SCCHN	3	0.001	0.061	1.482 (0.982–2.237)	1.415 (1.226–1.633)
	Cervical cancer	6	0.861	0.003*	1.339 (1.107–1.619)	1.338 (1.106–1.618)
	Esophageal cancer	4	0.020	0.910	1.022 (0.706–1.477)	1.050 (0.870–1.267)
	Gastric cancer	4	0.477	0.522	1.058 (0.892–1.255)	1.057 (0.892–1.254)
	Lung cancer	5	<0.001	0.694	0.943 (0.704–1.263)	1.045 (0.935–1.167)
	P-B	20	<0.001	0.130	1.112 (0.969–1.275)	1.124 (1.043–1.211)
	H-B	16	<0.001	0.012*	1.204 (1.042–1.392)	1.234 (1.139–1.337)
	HWE(Y)	32	<0.001	0.010*	1.138 (1.032–1.255)	1.150 (1.084–1.221)
	HWE(N)	4	<0.001	0.376	1.223 (0.783–1.911)	1.315 (1.143–1.512)

Continued over

Table 2 Results of pooled analysis for *TP73 G4C14-A4T14* polymorphism and cancer susceptibility (Continued)

Comparison	Subgroup	N	P_H	P_Z	Random	Fixed
BB vs. BA+AA	Overall	36	<0.001	0.021*	1.273 (1.038–1.563)	1.374 (1.227–1.538)
	Caucasian	14	<0.001	0.046*	1.509 (1.008–2.261)	1.697 (1.437–2.005)
	Asian	22	0.074	0.097	1.160 (0.951–1.415)	1.141 (0.976–1.332)
	Breast cancer	3	0.172	0.798	0.984 (0.388–2.493)	1.075 (0.617–1.875)
	Colorectal cancer	4	0.512	0.002*	1.746 (1.228–2.484)	1.760 (1.241–2.496)
	SCCHN	3	0.416	0.642	1.075 (0.782–1.477)	1.078 (0.786–1.477)
	Cervical cancer	6	0.913	0.349	0.825 (0.530–1.286)	0.811 (0.524–1.256)
	Esophageal cancer	4	0.052	0.688	1.193 (0.504–2.824)	1.165 (0.764–1.777)
	Gastric cancer	4	0.717	0.118	1.342 (0.934–1.927)	1.334 (0.929–1.915)
	Lung cancer	5	0.006	0.794	0.938 (0.578–1.521)	1.029 (0.818–1.294)
	P-B	20	0.006	0.532	1.086 (0.839–1.404)	1.106 (0.945–1.296)
	H-B	16	<0.001	0.005*	1.545 (1.139–2.094)	1.734 (1.474–2.039)
	HWE(Y)	32	<0.001	0.011*	1.309 (1.063–1.613)	1.446 (1.280–1.633)
	HWE(N)	4	0.003	0.743	1.145 (0.509–2.579)	1.000 (0.736–1.358)

P_H : P value of Q-test for heterogeneity test; P_Z : means statistically significant ($P < 0.05$); HWE, Hardy–Weinberg equilibrium; N, polymorphisms did not conform to HWE in the control group; P-B, population based; SCCHN, squamous cell carcinoma of the head and neck; Y, polymorphisms conformed to HWE in the control group; *P value less than 0.05 was considered as statistically significant.


Figure 2. Meta-analysis of the association between *TP73 G4C14-A4T14* polymorphism and overall cancer risk

$P=0.011$), homozygote comparison model (GC/GC vs. AT/AT: OR = 1.820, 95% CI = 1.270–2.608, $P=0.001$) and recessive comparison model (GC/GC vs. GC/AT+AT/AT: OR = 1.760, 95% CI = 1.241–2.496, $P=0.002$). As to cervical cancer, there are also some interesting results. The meta-analysis revealed an increasing risk of cancer caused by *G4C14-A4T14* polymorphism in allelic contrast model (GC vs. AT: OR = 1.189, 95% CI = 1.016–1.392, $P=0.031$), heterozygote comparison model (GC/AT vs. AT/AT: OR = 1.413, 95% CI = 1.159–1.722, $P=0.001$) and dominant comparison model (GC/GC+GC/AT vs. AT/AT: OR = 1.338, 95% CI = 1.106–1.618, $P=0.003$) (Table 2, Figure 4). We also performed subgroup analysis of breast cancer, esophageal cancer, gastric cancer, lung cancer and squamous




Figure 3. Meta-analysis of the association between *TP73 G4C14-A4T14* polymorphism and colorectal cancer risk




Figure 4. Meta-analysis of the association between *TP73 G4C14-A4T14* polymorphism and cervical cancer risk

cell carcinoma of the head and neck, no significant association was found between *G4C14-A4T14* polymorphism and these carcinomas in all five genetic models (Table 2 and Figures S1–S4).

Stratification analysis by ethnicity

There was some significant result shown in subgroup analysis of ethnicity. The 14 Caucasian based case-control studies shown a significantly increasing risk between *G4C14-A4T14* polymorphism and cancer in allelic contrast model (GC vs. AT: OR = 1.279, 95% CI = 1.131–1.446, $P < 0.001$), homozygote comparison model (GC/GC vs. AT/AT: OR = 1.649, 95% CI = 1.119–2.431, $P < 0.001$), heterozygote comparison model (GC/AT vs. AT/AT: OR = 1.252, 95% CI = 1.061–1.477, $P < 0.001$), dominant comparison model (GC/GC+GC/AT vs. AT/AT: OR = 1.312, 95% CI = 1.140–1.511, $P = 0.004$) and recessive comparison model (GC/GC vs. GC/AT+AT/AT: OR = 1.509, 95% CI = 1.008–2.261, $P < 0.001$) (Table 2 and Figure S5).




Figure 5. Begg's funnel plot for publication bias test for *TP73 G4C14-A4T14* polymorphism (GC vs. AT)

The x-axis is $\log(\text{OR})$, and the y-axis is natural logarithm of OR. The horizontal line in the figure represents the overall estimated $\log(\text{OR})$. The two diagonal lines indicate the pseudo 95% confidence limits of the effect estimate.

Stratification analysis by source of control

Due to there are 20 case-control studies based on population controls, whereas another 16 studies enrolled hospital-based controls, we performed the stratified analysis by HWE status to obtain more precise results. The remarkable result shown a noticeable upgrade cancer risk of *G4C14-A4T14* polymorphism of the hospital-based control subgroup in allelic contrast model (GC vs. AT: OR = 1.213, 95%CI = 1.079–1.365, $P=0.001$), homozygote comparison model (GC/GC vs. AT/AT: OR = 1.625, 95% CI = 1.210–2.183 $P=0.001$), dominant comparison model (GC/GC+GC/AT vs. AT/AT: OR = 1.204, 95% CI = 1.042–1.392, $P=0.012$) and recessive comparison model (GC/GC vs. GC/AT+AT/AT: OR = 1.545, 95% CI = 1.139–2.094, $P=0.005$), while there was no significant result of the heterozygote comparison model (GC/AT vs. AT/AT: OR = 1.134, 95% CI = 0.964–1.334, $P=0.129$). Nevertheless, there are no significant result revealed in population-based control subgroup in overall cancer (Table 2 and Figure S6).

Stratification analysis by HWE status

In order to exclude the influence of allele frequency changing, we calculated whether the control group conform to HWE, and conducted the stratification meta-analysis in subgroups of HWE status. As shown in Table 2 and Figure S7, the subgroup that conforms to HWE was uncovered responsible to the remarkable increasing cancer risk of *G4C14-A4T14* polymorphism in allelic contrast model (GC vs. AT: OR = 1.138, 95%CI = 1.044–1.239, $P=0.003$), homozygote comparison model (GC/GC vs. AT/AT: OR = 1.342, 95% CI = 1.085–1.659, $P=0.007$), dominant comparison model (GC/GC+GC/AT vs. AT/AT: OR = 1.138, 95% CI = 1.032–1.255, $P=0.010$) and recessive comparison model (GC/GC vs. GC/AT+AT/AT: OR = 1.309, 95% CI = 1.063–1.613, $P=0.011$), whereas the other four case-control studies that do not conform to HWE did not influence the result in overall cancer (Table 2 and Figure S7).

Sensitivity analysis and publication bias

Sensitivity analysis was performed to assess the influence of each individual study on the pooled OR by sequential removal of individual studies, the results showed that the study material alteration did not influence the corresponding pooled ORs for the overall meta-analysis (Figure 5 and Table S3). In addition, Begg's funnel plot and Egger's test were presented to assess the potential publication bias, no evidence of publication bias was revealed by evaluating the shape of Begg's funnel plot and by Egger's regression test (Figures S8, S9 and Table S4).

Result of FPRP and TSA

The FPRP values for significant findings at different prior probability levels are shown in Table 3. In the result of overall group in five genetic models, all the statistical power is about 1, and the FPRP values are all less than 0.2,

Table 3 False-positive report probability values for associations between the risk of cancer and the frequency of genotypes of TP73 Gene

Comparison	Subgroup	P_z	OR (95% CI)	Statistical power*		Prior probability			
				0.250	0.1	0.01	0.001	0.0001	
B vs. A	Overall	0.002	1.139 (1.048–1.238)	1.000	<0.001	<0.001	0.001	0.006	0.053
	Caucasian	<0.001	1.279 (1.131–1.446)	0.809	<0.001	<0.001	0.001	0.006	0.054
	Colorectal cancer	0.011	1.204 (1.044–1.389)	0.754	<0.001	<0.001	0.001	0.007	0.062
	Cervical cancer	0.031	1.189 (1.016–1.392)	0.446	<0.001	<0.001	0.001	0.008	0.075
	H-B	0.001	1.213 (1.079–1.365)	1.000	<0.001	<0.001	0.001	0.006	0.054
	HWE(Y)	0.003	1.138 (1.044–1.239)	1.000	<0.001	<0.001	0.001	0.006	0.053
BB vs. AA	Overall	0.009	1.320 (1.071–1.627)	1.000	<0.001	<0.001	0.002	0.024	0.196
	Caucasian	0.011	1.649 (1.119–2.431)	0.467	0.003	0.008	0.081	0.469	0.898
	Colorectal cancer	0.001	1.820 (1.270–2.608)	0.901	0.002	0.005	0.053	0.362	0.850
	H-B	0.001	1.625 (1.210–2.183)	1.000	0.001	0.002	0.017	0.148	0.635
	HWE(Y)	0.007	1.342 (1.085–1.659)	1.000	<0.001	<0.001	0.003	0.025	0.208
BA vs. AA	Overall	0.028	1.123 (1.012–1.245)	0.992	<0.001	<0.001	0.001	0.006	0.053
	Caucasian	0.008	1.252 (1.061–1.477)	0.557	<0.001	<0.001	0.001	0.009	0.085
	Cervical cancer	0.001	1.413 (1.159–1.722)	0.822	<0.001	<0.001	0.002	0.018	0.157
BB+BA vs. AA	Overall	0.005	1.152 (1.044–1.272)	1.000	<0.001	<0.001	0.001	0.006	0.053
	Caucasian	<0.001	1.312 (1.140–1.511)	0.703	<0.001	<0.001	0.001	0.006	0.061
	Cervical cancer	0.003	1.338 (1.106–1.618)	0.714	<0.001	<0.001	0.002	0.015	0.135
	H-B	0.012	1.204 (1.042–1.392)	1.000	<0.001	<0.001	0.001	0.007	0.064
	HWE(Y)	0.010	1.138 (1.032–1.255)	0.996	<0.001	<0.001	0.001	0.006	0.053
BB vs. BA+AA	Overall	0.021	1.273 (1.038–1.563)	1.000	<0.001	<0.001	0.002	0.022	0.182
	Caucasian	0.046	1.509 (1.008–2.261)	0.341	0.003	0.010	0.100	0.528	0.918
	Colorectal cancer	0.002	1.760 (1.241–2.496)	0.888	0.001	0.004	0.045	0.323	0.827
	H-B	0.005	1.545 (1.139–2.094)	1.000	0.001	0.002	0.020	0.172	0.675
	HWE(Y)	0.011	1.309 (1.063–1.613)	1.000	<0.001	<0.001	0.002	0.024	0.195

CI, confidence interval; H-B, hospital based; HWE(Y), Polymorphisms conformed to Hardy–Weinberg equilibrium in the control group; OR, odds ratio.

*Statistical power was calculated using the number of observations in the subgroup and the OR and P values in this table.

under the prior probability of 0.1. On the subgroup of cervical cancer and colorectal cancer, the FPRP values are also less than 0.2. The result of TSA is shown in Figure 6, the required sample size is 21,728 samples, and the cumulative z -curve crossed the trial sequential monitoring boundary before reaching the required sample size, which means that our conclusions are robust with these sufficient evidence.




Figure 6. Trial sequential analysis for *TP73* G4C14-A4T14 polymorphism under the allele contrast model

In silico analysis of *TP73* expression

In silico analysis, we draw out the correlation between *TP73* expression and breast invasive carcinoma, cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), colon adenocarcinoma (COAD), esophageal carcinoma, head and neck squamous cell carcinoma, lung adenocarcinoma, lung squamous cell carcinoma (LUSC), ovarian serous, prostate adenocarcinoma, rectum adenocarcinoma, skin cutaneous melanoma, Ssomach adenocarcinoma, with the help of GEPIA web server. The result indicated that the expression of *TP73* in tumor tissue is higher than it in corresponding normal tissue of CESC (TPM = 9.60 vs. 0.58 respectively, $P < 0.01$), COAD (TPM = 1.93 vs. 0.56 respectively, $P < 0.01$), LUSC (TPM = 7.64 vs. 1.07 respectively, $P < 0.01$), whereas lower than it in normal tissue of SKCM (TPM = 0.67 vs. 7.62 respectively, $P < 0.01$) (Figure S10).

Discussion

TP73 gene is located at chromosome 1p36 and comprises 15 exons [54]. *TP73* could be transcribed from two individual promoters, one is in the upstream of exon 1, it could produce p53-like proteins containing transactivation domain (TAp73) and another TA lacking protein (Δ TAp73). The second promoter is situated in intron 3, it could turn out the N-terminal truncated isoform (Δ Np73) [55]. What's more, both TAp73 and Δ Np73 undergo the alternative splicing and initiation of translation, and lead to several splicing isoforms [56,57]. While sharing the similar sequence with p53, TAp73 could activate the expression of downstream genes through specifically binding domain of p53 response element, regulating cell apoptosis or cell-cycle arrest [58,59]. On the meanwhile, Δ Np73 could present a potent anti-oncogenic function through inhibiting the key role of TAp63, TAp73 or p53 [60]. Several publications had reported that the *TP73* expression plays critical role in tumorigenesis, combined with different isoforms or several mutations [61–64].

In the past decades, almost 146 unique variations had been reported (shown in the Biomuta database [65]), while numerous studies had probed into the relationship of G4C14-A4T14 polymorphism and cancer genomics. G4A (*rs2273953*) and C14T (*rs1801173*) polymorphisms are located at position 4 (G to A) and 14 (C to T) of exon 2 5'-untranslated region, which might influence the initiating AUG codon through constructing a stem-loop [54]. Zheng et al. [40] and Niwa et al. [34] reported that G4C14-A4T14 polymorphism was not associated with the cancer susceptibility of cervical cancer in Uighur and Japanese, respectively. However, Craveiro et al. [51] revealed that G4C14-A4T14 polymorphism leads to an increasing risk of cervical cancer, as well as the newest study conducted by Feng et al. [17]. As colorectal cancer, Hamajima et al. [28] presented that no significant differences in the genotype frequencies were observed among the enrolled cases and controls in his study. On the contrast, Lee et al. [47] reported

that GC/AT and AT/AT genotypes were significantly associated with colorectal cancer risk in Korean population. Arfaoui et al. [66] also uncovered that no remarkable differences of genotype frequencies in cancers and controls, but they found that AT/AT genotype might cause the poor prognosis of colorectal cancer. Several researches also managed in lung cancer. Hu et al. [35] indicated that both AT/AT and GC/AT variants were associated with a remarkable decreased risk for lung cancer, distinguisingly, Li et al. [64] suggested that the AT/AT and GC/AT genotypes were related with a statistically significantly increased risk for lung cancer. Choi et al. [38] did not agree with each of them, they revealed that *TP73 G4C14-A4T14* polymorphism does not affect the susceptibility to lung cancer in Korean population.

Among these publications concerned about *G4C14-A4T14* polymorphism and cancer risk, the result is not consistent. Liang et al. [67] conducted a meta-analysis about *G4C14-A4T14* polymorphism and cervical cancer, they only enrolled 5 studies, as well as Liu et al. [68], they only enrolled 5 studies about lung cancer. Yu et al. [69] had performed a meta-analysis with only 23 eligible studies; however, they draw a decreased risk of *G4C14-A4T14* polymorphism, this mistake may cause by the fewer samples. Therefore, our team carried out the present comprehensive meta-analysis aiming at shedding light on the multiple lines of evidence. Finally, 36 case-control studies comprise 9493 cases and 13,157 controls were enrolled and analyzed. All in all, our recent updated meta-analysis draws a comprehensive, precise and convincible result, which is that *G4C14-A4T14* polymorphism of *TP73* is strongly associated with the increasing cancer risk, especially for Caucasian, cervical cancer and colorectal cancer. Therefore, in the future, *G4C14-A4T14* polymorphism might be a useful diagnostic marker for cervical cancer and colorectal cancer, especially in Caucasian population. On the other hand, for researchers, other polymorphisms of *TP73* should be focused on to assess whether they change cancer risks.

The current result about *G4C14-A4T14* polymorphism and cancer risk should be cautiously interpreted, because there are some limitations. First, an insufficient capacity that slight effects on cancer susceptibility occurred when a stratified analysis was conducted by the cancer type, ethnicity and source of control. Second, several potential confounding factors were ignored, such as age, gender, smoking, drinking and etc., so we are unable to perform a further assessment of potential gene-environment interactions. Third, we only enrolled publications written in English or Chinese, missing publications from other languages may cause potential bias. On the meanwhile, the advantages of this research should not be buried. First, a comprehensive search was conducted to identify more qualified studies, so this analysis is persuasive and substantive. Second, the quality of each registered research was evaluated by NOS scale, low-quality studies were eliminated to raise the credibility of results. Third, stratification analysis was performed by ethnicity, source of controls, tumor type or ethnicity, in order to decrease the impact of heterogeneity and obtain the real conclusion.

In conclusion, our meta-analysis had successfully elaborated that *TP73 G4C14-A4T14* polymorphism causes an upgrade cancer risk, especially in Caucasian population. *G4C14-A4T14* polymorphism might be a potential biomarker for judging the tumorigenesis of cervical cancer and colorectal cancer.

Author Contribution

M.J.L. and W.S. accessed information from literature for this article. M.J.L., Z.M. and F.S. designed and performed the meta-analysis. M.J.L., Z.L. and L.C.Z. contributed toward writing, discussing and editing the manuscript. All authors discussed the results and contributed to the final manuscript.

Funding

This manuscript was supported by National Natural Science Foundation of China [81630019 (to L.C.Z)].

Competing Interests

The authors declare that there are no competing interests associated with the manuscript.

Abbreviations

CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; COAD, colon adenocarcinoma; HWE, Hardy-Weinberg equilibrium; LUSC, lung squamous cell carcinoma; NOS, Newcastle-Ottawa Scale; SNP, single-nucleotide polymorphism; TSA, trial sequential analysis; TP73, tumor protein P73.

References

- 1 Siegel, R.L., Miller, K.D. and Jemal, A. (2018) Cancer statistics, 2018. *CA Cancer J. Clin.* **68**, 7–30, <https://doi.org/10.3322/caac.21442>
- 2 Chen, W., Zheng, R., Baade, P.D., Zhang, S., Zeng, H. and Bray, F. (2016) Cancer statistics in China, 2015. *CA Cancer J. Clin.* **66**, 115–132, <https://doi.org/10.3322/caac.21338>

- 3 Vineis, P. and Fecht, D. (2018) Environment, cancer and inequalities – the urgent need for prevention. *Eur. J. Cancer*, <https://doi.org/10.1016/j.ejca.2018.04.018>
- 4 Tanaka, T., Watanabe, M. and Yamashita, K. (2018) Potential therapeutic targets of TP53 gene in the context of its classically canonical functions and its latest non-canonical functions in human cancer. *Oncotarget* **9**, 16234–16247, <https://doi.org/10.1863/oncotarget.24611>
- 5 Tidwell, T.R., Soreide, K. and Hagland, H.R. (2017) Aging, metabolism, and cancer development: from Peto's Paradox to the Warburg Effect. *Aging Dis.* **8**, 662–676, <https://doi.org/10.14336/AD.2017.0713>
- 6 Tozluoglu, M., Karaca, E., Haliloglu, T. and Nussinov, R. (2008) Cataloging and organizing p73 interactions in cell cycle arrest and apoptosis. *Nucleic Acids Res.* **36**, 5033–5049, <https://doi.org/10.1093/nar/gkn481>
- 7 Jost, C.A., Marin, M.C. and Kaelin, Jr., W.G. (1997) p73 is a simian [correction of human] p53-related protein that can induce apoptosis. *Nature* **389**, 191–194, <https://doi.org/10.1038/38298>
- 8 Candi, E., Agostini, M., Melino, G. and Bernassola, F. (2014) How the TP53 family proteins TP63 and TP73 contribute to tumorigenesis: regulators and effectors. *Hum. Mutat.* **35**, 702–714, <https://doi.org/10.1002/humu.22523>
- 9 Monti, P., Ghiorzo, P., Menichini, P., Foggetti, G., Queirolo, P. and Izzotti, A. (2017) TP63 mutations are frequent in cutaneous melanoma, support UV etiology, but their role in melanomagenesis is unclear. *Oncol. Rep.* **38**, 1985–1994
- 10 Vilgelm, A.E., Washington, M.K., Wei, J., Chen, H., Prassolov, V.S. and Zaika, A.I. (2010) Interactions of the p53 protein family in cellular stress response in gastrointestinal tumors. *Mol. Cancer Ther.* **9**, 693–705, <https://doi.org/10.1158/1535-7163.MCT-09-0912>
- 11 Leviero, M., De Laurenzi, V., Costanzo, A., Gong, J., Wang, J.Y. and Melino, G. (2000) The p53/p63/p73 family of transcription factors: overlapping and distinct functions. *J. Cell Sci.* **113**, 1661–1670
- 12 Kaghad, M., Bonnet, H., Yang, A., Creancier, L., Biscan, J.C. and Valent, A. (1997) Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. *Cell* **90**, 809–819, [https://doi.org/10.1016/S0092-8674\(00\)80540-1](https://doi.org/10.1016/S0092-8674(00)80540-1)
- 13 Peters, M.A., Janer, M., Kolb, S., Jarvik, G.P., Ostrander, E.A. and Stanford, J.L. (2001) Germline mutations in the p73 gene do not predispose to familial prostate-brain cancer. *Prostate* **48**, 292–296, <https://doi.org/10.1002/pros.1109>
- 14 Umar, M., Upadhyay, R., Khurana, R., Kumar, S., Ghoshal, U.C. and Mittal, B. (2012) Role of p53 and p73 genes polymorphisms in susceptibility to esophageal cancer: a case control study in a northern Indian population. *Mol. Biol. Rep.* **39**, 1153–1162, <https://doi.org/10.1007/s11033-011-0844-9>
- 15 Zhou, X. and Wu, C. (2012) Association of p73 G4C14-A4T14 polymorphisms with genetic susceptibilities to breast cancer: a case-control study. *Chin. J. Clin. Oncol.* **29**, 3216–3221
- 16 Wang, S.S., Guo, H.Y., Dong, L.L., Zhu, X.Q., Ma, L. and Li, W. (2014) Association between a p73 gene polymorphism and genetic susceptibility to non-small cell lung cancer in the South of China. *Asian. Pac. J. Cancer Prev.* **15**, 10387–10391, <https://doi.org/10.7314/APJCP.2014.15.23.10387>
- 17 Feng, H., Sui, L., Du, M. and Wang, Q. (2017) Meta-analysis of TP73 polymorphism and cervical cancer. *Genet. Mol. Res.* **16**, <https://doi.org/10.4238/gmr16016571>
- 18 Lau, J., Ioannidis, J.P. and Schmid, C.H. (1997) Quantitative synthesis in systematic reviews. *Ann. Internal Med.* **127**, 820–826, <https://doi.org/10.7326/0003-4819-127-9-19971101-00008>
- 19 R, D. and N, L. (1986) Meta-analysis in clinical trials. *Control. Clin. Trials* **7**, 177, [https://doi.org/10.1016/0197-2456\(86\)90046-2](https://doi.org/10.1016/0197-2456(86)90046-2)
- 20 Begg, C.B. and Mazumdar, M. (1994) Operating characteristics of a rank correlation test for publication bias. *Biometrics* **50**, 1088–1101, <https://doi.org/10.2307/2533446>
- 21 Higgins, J.P. and Thompson, S.G. (2002) Quantifying heterogeneity in a meta-analysis. *Stat. Med.* **21**, 1539–1558, <https://doi.org/10.1002/sim.1186>
- 22 Wacholder, S., Chanock, S., Garcia-Closas, M., El Ghormli, L. and Rothman, N. (2004) Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. *J. Natl. Cancer Inst.* **96**, 434–442, <https://doi.org/10.1093/jnci/djh075>
- 23 He, J., Wang, M.Y., Qiu, L.X., Zhu, M.L., Shi, T.Y. and Zhou, X.Y. (2013) Genetic variations of mTORC1 genes and risk of gastric cancer in an Eastern Chinese population. *Mol. Carcinog.* **52**, E70–E79
- 24 Tang, Z., Li, C., Kang, B., Gao, G., Li, C. and Zhang, Z. (2017) GEPiA: a web server for cancer and normal gene expression profiling and interactive analyses. *Nucleic Acids Res.* **45**, W98–W102, <https://doi.org/10.1093/nar/gkx247>
- 25 Romani, M., Scaruffi, P., Casciano, I., Mazzocco, K., Lo Cunsolo, C. and Cavazzana, A. (1999) Stage-independent expression and genetic analysis of tp73 in neuroblastoma. *Int. J. Cancer* **84**, 365–369, [https://doi.org/10.1002/\(SICI\)1097-0215\(19990820\)84:4%3c365::AID-IJC6%3e3.0.CO;2-X](https://doi.org/10.1002/(SICI)1097-0215(19990820)84:4%3c365::AID-IJC6%3e3.0.CO;2-X)
- 26 Ahomadegbe, J.C., Tourpin, S., Kaghad, M., Zelek, L., Vayssade, M. and Mathieu, M.C. (2000) Loss of heterozygosity, allele silencing and decreased expression of p73 gene in breast cancers: prevalence of alterations in inflammatory breast cancers. *Oncogene* **19**, 5413–5418
- 27 Ryan, B.M., Mcmanus, R., Daly, J.S., Carton, E., Keeling, P.W. and Reynolds, J.V. (2001) A common p73 polymorphism is associated with a reduced incidence of oesophageal carcinoma. *Br. J. Cancer* **85**, 1499–1503
- 28 Hamajima, N., Matsuo, K., Suzuki, T., Nakamura, T., Matsuura, A. and Hatooka, S. (2002) No associations of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro polymorphisms with the risk of digestive tract cancers in Japanese. *Cancer Lett.* **181**, 81–85, [https://doi.org/10.1016/S0304-3835\(02\)00041-1](https://doi.org/10.1016/S0304-3835(02)00041-1)
- 29 Hiraki, A., Matsuo, K., Hamajima, N., Ito, H., Hatooka, S. and Suyama, M. (2003) Different risk relations with smoking for non-small-cell lung cancer: comparison of TP53 and TP73 genotypes. *Asian Pac. J. Cancer Prev.* **4**, 107
- 30 Huang, X.E., Hamajima, N., Katsuda, N., Matsuo, K., Hirose, K. and Mizutani, M. (2003) Association of p53 codon arg72pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer. *Breast Cancer* **10**, 307–311
- 31 Hishida, A., Matsuo, K., Tajima, K., Ogura, M., Kagami, Y. and Taji, H. (2004) Polymorphisms of p53 Arg72Pro, p73 G4C14-to-A4T14 at Exon 2 and p21 Ser31Arg and the risk of non-Hodgkin's Lymphoma in Japanese. *Leukemia Lymphoma* **45**, 957–964, <https://doi.org/10.1080/10428190310001638878>
- 32 Li, G., Sturgis, E.M., Wang, L.E., Chamberlain, R.M., Amos, C.I. and Spitz, M.R. (2004) Association of a p73 exon 2 G4C14-to-A4T14 polymorphism with risk of squamous cell carcinoma of the head and neck. *Carcinogenesis* **25**, 1911, <https://doi.org/10.1093/carcin/bgh197>

- 33 Li, G., Wang, L.E., Chamberlain, R.M., Amos, C.I., Spitz, M.R. and Wei, Q. (2004) p73 G4C14-to-A4T14 polymorphism and risk of lung cancer. *Cancer Res.* **64**, 6863, <https://doi.org/10.1158/0008-5472.CAN-04-1804>
- 34 Niwa, Y., Hamajima, N., Atsuta, Y., Yamamoto, K., Tamakoshi, A. and Saito, T. (2004) Genetic polymorphisms of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro and the risk of cervical cancer in Japanese. *Cancer Lett.* **205**, 55–60, <https://doi.org/10.1016/j.canlet.2003.11.014>
- 35 Hu, Z., Miao, X., Ma, H., Tan, W., Wang, X. and Lu, D. (2005) Dinucleotide polymorphism of p73 gene is associated with a reduced risk of lung cancer in a Chinese population. *Int. J. Cancer* **114**, 455–460, <https://doi.org/10.1002/ijc.20746>
- 36 Niwa, Y., Hirose, K., Matsuo, K., Tajima, K., Ikoma, Y. and Nakanishi, T. (2005) Association of p73 G4C14-to-A4T14 polymorphism at exon 2 and p53 Arg72Pro polymorphism with the risk of endometrial cancer in Japanese subjects. *Cancer Lett.* **219**, 183–190, <https://doi.org/10.1016/j.canlet.2004.10.018>
- 37 Pfeifer, D., Arbman, G. and Sun, X.F. (2005) Polymorphism of the p73 gene in relation to colorectal cancer risk and survival. *Carcinogenesis* **26**, 103–107, <https://doi.org/10.1093/carcin/bgh305>
- 38 Choi, J.E., Kang, H.G., Chae, M.H., Kim, E.J., Lee, W.K. and Cha, S.I. (2006) No association between p73 G4C14-to-A4T14 polymorphism and the risk of lung cancer in a Korean population. *Biochem. Genet.* **44**, 543, <https://doi.org/10.1007/s10528-006-9056-8>
- 39 Ge, H., Wang, Y., Cao, Y., Zhang, X. and Yan, L. (2006) Correlation of p73 polymorphisms to genetic susceptibilities to esophageal carcinoma and gastric cardiac carcinoma. *Chinese J. Cancer* **25**, 1351–1355
- 40 Zheng, L. (2006) *Association of p53 Arg72Pro Polymorphism, p73G4A Polymorphism with Cervical Cancer in Xinjiang Uygur Population*, Shihezi University
- 41 Chen, X., Sturgis, E.M., Elnaggar, A.K., Wei, Q. and Li, G. (2008) Combined effects of the p53 codon 72 and p73 G4C14-to-A4T14 polymorphisms on the risk of HPV16-associated oral cancer in never-smokers. *Carcinogenesis* **29**, 2120, <https://doi.org/10.1093/carcin/bgn191>
- 42 Li, C., Chen, K., Liu, Z., Wang, L., Gershenwald, J.E. and Lee, J.E. (2008) Polymorphisms of TP53 Arg72Pro, but not p73 G4C14>A4TA4 and p21 Ser31Arg, contribute to risk of cutaneous melanoma. *J. Invest. Dermatol.* **128**, 1585–1588, <https://doi.org/10.1038/sj.jid.5701186>
- 43 Feo, E.D., Persiani, R., Greca, A.L., Amore, R., Arzani, D. and Rausei, S. (2009) A case-control study on the effect of p53 and p73 gene polymorphisms on gastric cancer risk and progression. *Mut. Res.* **675**, 60–65, <https://doi.org/10.1016/j.mrgentox.2009.02.009>
- 44 Kang, S., Wang, D.J., Li, W.S., Wang, N., Zhou, R.M. and Sun, D.L. (2009) Association of p73 and MDM2 polymorphisms with the risk of epithelial ovarian cancer in Chinese women. *Int. J. Gynecol. Cancer* **19**, 572–577, <https://doi.org/10.1111/IGC.0b013e3181a130ab>
- 45 Misra, C., Majumder, M., Bajaj, S., Ghosh, S., Roy, B. and Roychoudhury, S. (2009) Polymorphisms at p53, p73, and MDM2 loci modulate the risk of tobacco associated leukoplakia and oral cancer. *Mol. Carcinog.* **48**, 790–800, <https://doi.org/10.1002/mc.20523>
- 46 Arfaoui, A.T., Kriaa, L.B., El HOA, Ben Hmida, M.A., Khiali, M. and Khalfallah, T. (2010) Association of a p73 exon 2 GC/AT polymorphism with colorectal cancer risk and survival in Tunisian patients. *Virchows Archiv.* **457**, 359–368, <https://doi.org/10.1007/s00428-010-0942-4>
- 47 Lee, K.E., Hong, Y.S., Kim, B.G., Kim, N.Y., Lee, K.M. and Kwak, J.Y. (2010) p73 G4C14 to A4T14 polymorphism is associated with colorectal cancer risk and survival. *World J. Gastroenterol.* **16**, 4448, <https://doi.org/10.3748/wjg.v16.135.4448>
- 48 Shirai, O., Ohmiya, N., Taguchi, A., Nakamura, M., Kawashima, H. and Miyahara, R. (2010) P53, p21, and p73 gene polymorphisms in gastric carcinoma. *Hepatogastroenterology* **57**, 1595
- 49 Mittal, R.D., George, G.P., Mishra, J., Mittal, T. and Kapoor, R. (2011) Role of functional polymorphisms of P53 and P73 genes with the risk of prostate cancer in a case-control study from Northern India. *Arch. Med. Res.* **42**, 122–127, <https://doi.org/10.1016/j.arcmed.2011.03.001>
- 50 Li-li, Z., Xiao-lin, P., An-qiang, Y., Xing-zheng, Z., Xiao-ling, W. and Qiu-yuan, Z. (2008) Study of p73G4A polymorphism in HPV-associated cervical carcinoma in Uygur woman in Xinjiang. *China J. Modern Med.* **18**, 2302–2306
- 51 Craveiro, R., Bravo, I., Catarino, R., Teixeira, A.L., Sousa, H. and Pereira, D. (2012) The role of p73 G4C14-to-A4T14 polymorphism in the susceptibility to cervical cancer. *DNA Cell Biol.* **31**, 224, <https://doi.org/10.1089/dna.2011.1294>
- 52 Sun, L., Zhu, Z., Ni, G. and Zhu, X. (2012) Correlation of P73 polymorphisms to genetic susceptibilities to cervical carcinoma and Meta-analysis. *Basic Clin. Med.* **32**, 1421–1425
- 53 Zhang, X., Cao, P., Zhai, Y., Zhang, H., Cui, Y. and Wu, Z. (2014) Association between the p73 G4C14-to-A4T14 polymorphism and risk of nasopharyngeal carcinoma: a case control and family-based study. *Carcinogenesis* **35**, 1977–1982
- 54 Kaghad, M., Bonnet, H., Yang, A., Creancier, L., Biscan, J.C. and Valent, A. (1997) Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. *Cell* **90**, 809–819, [https://doi.org/10.1016/S0092-8674\(00\)80540-1](https://doi.org/10.1016/S0092-8674(00)80540-1)
- 55 Conforti, F., Yang, A.L., Agostini, M., Rufini, A., Tucci, P. and Nicklison-chirou, M.V. (2012) Relative expression of TA_np73 and ΔNp73 isoforms. *Aging* **4**, 202–205, <https://doi.org/10.1863/aging.100441>
- 56 Murrayzmjewski, F., Lane, D.P. and Bourdon, J.C. (2006) p53[soI]p63[soI]p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. *Cell Death Differ.* **13**, 962, <https://doi.org/10.1038/sj.cdd.4401914>
- 57 De, V.L., Costanzo, A., Barcaroli, D., Terrinoni, A., Falco, M. and Annicchiaricopetrizzelli, M. (1998) Two new p73 splice variants, gamma and delta, with different transcriptional activity. *J. Exp. Med.* **188**, 1763–1768
- 58 Wang, J., Liu, Y.X., Hande, M.P., Wong, A.C., Jin, Y.J. and Yin, Y. (2007) TA_np73 is a downstream target of p53 in controlling the cellular defense against stress. *J. Biol. Chem.* **282**, 29152–29162, <https://doi.org/10.1074/jbc.M703408200>
- 59 Müller, M., Schleithoff, E.S., Stremmel, W., Melino, G., Krammer, P.H. and Schilling, T. (2006) One, two, three—p53, p63, p73 and chemosensitivity. *Drug Resist. Update.* **9**, 288–306, <https://doi.org/10.1016/j.drup.2007.01.001>
- 60 Moll, U.M. (2004) Slade N. p63 and p73: roles in development and tumor formation. *National Cancer Institute. Mol. Cancer Res.* **2**, 371
- 61 Rodríguez, N., Peláez, A., Barderas, R. and Domínguez, G. (2017) Clinical implications of the deregulated TP73 isoforms expression in cancer. *Clin. Transl. Oncol.* **20**, 1–10
- 62 Chen, J., Li, D., Killary, A.M., Sen, S., Amos, C.I. and Evans, D.B. (2009) Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation. *Ann. Surg. Oncol.* **16**, 431, <https://doi.org/10.1245/s10434-008-0220-8>

- 63 Coates, P.J. (2006) Regulating p73 isoforms in human tumours. *J. Pathol.* **210**, 385, <https://doi.org/10.1002/path.2080>
- 64 Li, G., Sturgis, E.M., Wang, L., Chamberlain, R.M., Amos, C.I. and Spitz, M.R. (2004) Association of a p73 exon 2 G4C14-to-A4T14 polymorphism with risk of squamous cell carcinoma of the head and neck. *Carcinogenesis* **25**, 1911, <https://doi.org/10.1093/carcin/bgh197>
- 65 Dingerdissen, H.M., Torcivia-Rodriguez, J., Hu, Y., Chang, T.C., Mazumder, R. and Kahsay, R. (2018) BioMutant and BioXpress: mutation and expression knowledgebases for cancer biomarker discovery. *Nucleic Acids Res.* **46**, D1128–D1136, <https://doi.org/10.1093/nar/gkx907>
- 66 Arfaoui, A.T., Ben Mahmoud, L.K., Ben, H.A., Khiari, M., Mohamed, A.L. and Chaar, I. (2010) Relationship between p73 polymorphism and the immunohistochemical profile of the full-length (TAp73) and NH₂-truncated (Δ Np73) isoforms in Tunisian patients. *Appl. Immunohistochem. Mol. Morphol.* **18**, 546–554, <https://doi.org/10.1097/PAI.0b013e3181e9fe58>
- 67 Liang, X., Chen, B. and Zhong, J. (2017) Association of P73 polymorphisms with susceptibilities of cervical carcinoma: a meta-analysis. *Oncotarget* **8**, 57409–57413
- 68 Liu, H., Liang, Y., Liao, H., Li, L. and Wang, H. (2014) Association of p73 G4C14-to-A4T14 polymorphism with lung cancer risk. *Tumour Biol.* **35**, 9311–9316, <https://doi.org/10.1007/s13277-014-2061-3>
- 69 Yu, X.J., Fang, F. and Xie, J. (2011) Relationship between TP73 polymorphism (G4C14-A4T14) and cancer risk: a meta-analysis based on literatures. *Gene* **484**, 42–46, <https://doi.org/10.1016/j.gene.2011.05.022>

Supplementary tables and figures

Effect of G4C14-A4T14 Polymorphism on Tumor Protein 73 Gene to Cancer Susceptibility: A Systematic Review and Meta-Analysis.

Jialin Meng¹; Shuo Wang²; Meng Zhang¹; Song Fan¹; Li Zhang^{1*}; Chaozhao Liang^{1*}

1. Department of Urology, The First Affiliated Hospital of Anhui Medical University; Institute of Urology, Anhui Medical University; Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University, Hefei, Anhui, China.

2. The First Clinical College of Anhui Medical University, Hefei, Anhui, China.

Corresponding author:

Chaozhao Liang, MD, PhD, liang_chaozhao@ahmu.edu.cn;

Li Zhang, PhD, lzhang@ahmu.edu.

Running Title: Association between *TP73 G4C14-A4T14* polymorphism and cancer susceptibility

Supplementary table 1. Methodological quality of the included studies according to the Newcastle-Ottawa Scale.

SNP	Author	Year	Adequacy of Case Definition		Representativeness of the Cases	Selection of Controls	Definition of Controls	Comparability Cases/Controls	Ascertainment of Exposure	Same Method of Ascertainment	Non-response rate
			*	**							
rs2273953	Romain <i>et al.</i>	1999	*			*	*	**	*	*	NA
rs2273953	Ahomadegbe <i>et al.</i>	2000	*				*	*	*	*	NA
rs2273953	Ryan <i>et al.</i>	2001	*	*	*	*	*	**	*	*	NA
rs2273953	Hamajima <i>et al.</i>	2002	*	*			*	*	*	*	NA
rs2273953	Hamajima <i>et al.</i>	2002	*	*			*	*	*	*	NA
rs2273953	Hamajima <i>et al.</i>	2002	*	*			*	*	*	*	NA
rs2273953	Hiraki <i>et al.</i>	2003	*	*			*	*	*	*	NA
rs2273953	Huang <i>et al.</i>	2003	*	*	*	*	*	*	*	*	NA
rs2273953	Hishida <i>et al.</i>	2004	*	*			*	*	*	*	NA
rs2273953	Li(a) <i>et al.</i>	2004	*	*			*	**	*	*	NA
rs2273953	Li(b) <i>et al.</i>	2004	*	*			*	**	*	*	NA
rs2273953	Niwa(a) <i>et al.</i>	2004	*	*	*	*	*	*	*	*	NA
rs2273953	Hu <i>et al.</i>	2005	*	*			*	**	*	*	NA
rs2273953	Niwa(b) <i>et al.</i>	2005	*	*	*	*	*	*	*	*	NA
rs2273953	Pfeifer <i>et al.</i>	2005	*	*	*	*	*	**	*	*	NA
rs2273953	Choi <i>et al.</i>	2006	*	*	*	*	*	**	*	*	NA
rs2273953	Ge(a) <i>et al.</i>	2006	*	*			*	*	*	*	NA
rs2273953	Ge(a) <i>et al.</i>	2006	*	*			*	*	*	*	NA
rs2273953	Zheng <i>et al.</i>	2006	*	*			*	*	*	*	NA
rs2273953	Chen <i>et al.</i>	2008	*	*	*	*	*	**	*	*	NA
rs2273953	Li(c) <i>et al.</i>	2008	*		*	*	*	**	*	*	NA
rs2273953	Deo Feo <i>et al.</i>	2009	*	*			*	*	*	*	NA
rs2273953	Kang <i>et al.</i>	2009	*	*			*	**	*	*	NA
rs2273953	Misra <i>et al.</i>	2009	*	*			*	*	*	*	NA
rs2273953	Lee <i>et al.</i>	2010	*	*	*	*	*	**	*	*	NA
rs2273953	Shirai <i>et al.</i>	2010	*	*	*	*	*	*	*	*	NA
rs2273953	Arfaoui <i>et al.</i>	2010	*	*	*	*	*	**	*	*	NA
rs2273953	Mittal <i>et al.</i>	2011	*	*			*	**	*	*	NA

rs2273953	Craveiro <i>et al.</i>	2012	*	*	*	*	*	**	*	*	*	NA
rs2273953	Zheng <i>et al.</i>	2008	*	*	*	*	*	*	*	*	*	NA
rs2273953	Sun <i>et al.</i>	2012	*	*	*	*	*	*	*	*	*	NA
rs2273953	Umar <i>et al.</i>	2012	*	*	*	*	*	**	*	*	*	NA
rs2273953	Zhou <i>et al.</i>	2012	*	*	*	*	*	**	*	*	*	NA
rs2273953	Zhang <i>et al.</i>	2014	*	*	*	*	*	*	*	*	*	NA
rs2273953	Wang <i>et al.</i>	2014	*	*	*	*	*	**	*	*	*	NA
rs2273953	Feng <i>et al.</i>	2017	*	*		*	*	**	*	*	*	NA

This table identifies “high” quality choices with a “star”. A study can be awarded a maximum of 1 star for each numbered item within the Selection and Exposure categories. A maximum of 2 stars can be given for Comparability. *, Yes; NA, not applicable. ([http://www.ohri.ca/programs/clinical epidemiology/oxford.htm](http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm)).



Supplementary table 2 :PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	Page 1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	Page 2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	Page 3-4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	Page 3-4
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	N/A
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	Study selection: Page 4
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	Search strategy: Page 4
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	Search strategy: Page 4
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	Figure 1
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	Data extraction: Page 5
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	Data extraction: Page 5
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	Statistical analysis: Page5-6
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	Statistical analysis: Page5-6
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	Statistical analysis: Page5-6



Supplementary table 2 :PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	Statistical analysis: Page5-6
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	Statistical analysis: Page5-6
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	Description of studies: page 6-7
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	Table 1-2
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	Page 7-9
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	Page 7-9
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	Page 7-9
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	Page 10
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	Page 10
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	Page 10-12
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	Page 12
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	Page 12
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	Page 13

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed.1000097

For more information, visit: www.prisma-statement.org.

Supplementary table 3. Details of the sensitivity analyses for *TP73 G4C14-A4T14* polymorphism and cancer risk.

Comparison	Study omitted	Estimate	95% Confident Interval	Effect Model
B VS. A	Romain <i>et al.</i> (1999)	1.130111	(1.0389659-1.2292511)	Random
	Ahomadegbe <i>et al.</i> (2000)	1.133441	(1.0426028-1.2321934)	
	Ryan <i>et al.</i> (2001)	1.149084	(1.0569933-1.2491991)	
	Hamajima <i>et al.</i> (2002)	1.149048	(1.0568505-1.2492886)	
	Hamajima <i>et al.</i> (2002)	1.143688	(1.0504015-1.2452592)	
	Hamajima <i>et al.</i> (2002)	1.143968	(1.0506956-1.2455198)	
	Hiraki <i>et al.</i> (2003)	1.143300	(1.049834-1.2450864)	
	Huang <i>et al.</i> (2003)	1.144951	(1.051527-1.2466749)	
	Hishida <i>et al.</i> (2004)	1.130186	(1.0383892-1.2300983)	
	Li(a) <i>et al.</i> (2004)	1.136100	(1.0429964-1.2375143)	
	Li(b) <i>et al.</i> (2004)	1.136270	(1.0404902-1.2408674)	
	Niwa(a) <i>et al.</i> (2004)	1.132942	(1.0376155-1.2370261)	
	Hu <i>et al.</i> (2005)	1.130616	(1.0386425-1.2307329)	
	Niwa(b) <i>et al.</i> (2005)	1.140216	(1.0467455-1.2420339)	
	Pfeifer <i>et al.</i> (2005)	1.161382	(1.0749881-1.2547184)	
	Choi <i>et al.</i> (2006)	1.137864	(1.0454811-1.2384103)	
	Ge <i>et al.</i> (2006)	1.136584	(1.0425612-1.2390856)	
	Ge <i>et al.</i> (2006)	1.141614	(1.0472397-1.2444935)	
	Zheng <i>et al.</i> (2006)	1.138859	(1.0438092-1.2425637)	
	Chen <i>et al.</i> (2008)	1.137807	(1.0453632-1.2384263)	
	Li(c) <i>et al.</i> (2008)	1.141616	(1.0475813-1.2440913)	
	Zheng <i>et al.</i> (2008)	1.121979	(1.036285-1.2147598)	
	Deo Feo <i>et al.</i> (2009)	1.139758	(1.0467359-1.2410459)	
	Kang <i>et al.</i> (2009)	1.121993	(1.0340479-1.2174183)	
	Misra <i>et al.</i> (2009)	1.146506	(1.0533116-1.247947)	
	Lee <i>et al.</i> (2010)	1.136432	(1.0431769-1.2380246)	
	Shirai <i>et al.</i> (2010)	1.131226	(1.0381091-1.2326947)	
	Arfaoui <i>et al.</i> (2010)	1.142575	(1.0483176-1.2453082)	
	Mittal <i>et al.</i> (2011)	1.140907	(1.0476701-1.2424422)	

	Craveiro <i>et al.</i> (2012)	1.141550	(1.0484502-1.2429176)
	Sun <i>et al.</i> (2012)	1.150812	(1.0588705-1.2507372)
	Umar <i>et al.</i> (2012)	1.135496	(1.0422311-1.2371075)
	Zhou <i>et al.</i> (2012)	1.127594	(1.0368782-1.2262458)
	Zhang <i>et al.</i> (2014)	1.156271	(1.0662039-1.2539471)
	Wang <i>et al.</i> (2014)	1.131914	(1.0390542-1.2330716)
	Feng <i>et al.</i> (2017)	1.137936	(1.0446957-1.2394984)
	Combined	1.138912	(1.0476518-1.2381208)
BB vs. AA	Romain <i>et al.</i> (1999)	1.319278	(1.0667233-1.6316261)
	Ahomadegbe <i>et al.</i> (2000)	1.316493	(1.0663194-1.6253613)
	Ryan <i>et al.</i> (2001)	1.351274	(1.1013309-1.6579402)
	Hamajima <i>et al.</i> (2002)	1.321924	(1.0677318-1.6366303)
	Hamajima <i>et al.</i> (2002)	1.315825	(1.0620592-1.6302253)
	Hamajima <i>et al.</i> (2002)	1.313211	(1.0598292-1.6271713)
	Hiraki <i>et al.</i> (2003)	1.315345	(1.0612687-1.6302501)
	Huang <i>et al.</i> (2003)	1.316119	(1.060487-1.6333713)
	Hishida <i>et al.</i> (2004)	1.298030	(1.047896-1.6078711)
	Li(a) <i>et al.</i> (2004)	1.338100	(1.0834709-1.6525694)
	Li(b) <i>et al.</i> (2004)	1.329958	(1.0691391-1.6544045)
	Niwa(a) <i>et al.</i> (2004)	1.305424	(1.0454627-1.6300255)
	Hu <i>et al.</i> (2005)	1.287425	(1.0418331-1.5909095)
	Niwa(b) <i>et al.</i> (2005)	1.292725	(1.0471598-1.5958755)
	Pfeifer <i>et al.</i> (2005)	1.379596	(1.1278074-1.6875975)
	Choi <i>et al.</i> (2006)	1.330259	(1.0772062-1.6427583)
	Ge <i>et al.</i> (2006)	1.318780	(1.0623056-1.6371746)
	Ge <i>et al.</i> (2006)	1.317213	(1.0599747-1.636878)
	Zheng <i>et al.</i> (2006)	1.315040	(1.0564038-1.6369984)
	Chen <i>et al.</i> (2008)	1.333760	(1.0806208-1.6461972)
	Li(c) <i>et al.</i> (2008)	1.327111	(1.06957-1.6466649)
	Zheng <i>et al.</i> (2008)	1.263788	(1.0609929-1.5053436)
	Deo Feo <i>et al.</i> (2009)	1.304227	(1.0534731-1.6146679)
	Kang <i>et al.</i> (2009)	1.292150	(1.0452878-1.5973122)
	Misra <i>et al.</i> (2009)	1.320516	(1.0643915-1.638271)
			Random

Lee <i>et al.</i> (2010)	1.306278	(1.0520783-1.6218961)
Shirai <i>et al.</i> (2010)	1.303745	(1.0492596-1.6199538)
Arfaoui <i>et al.</i> (2010)	1.323549	(1.0655433-1.6440278)
Mittal <i>et al.</i> (2011)	1.337680	(1.0873282-1.6456749)
Craveiro <i>et al.</i> (2012)	1.324417	(1.0695929-1.6399503)
Sun <i>et al.</i> (2012)	1.355713	(1.1013395-1.6688389)
Umar <i>et al.</i> (2012)	1.325778	(1.0700411-1.6426341)
Zhou <i>et al.</i> (2012)	1.296641	(1.0498366-1.6014660)
Zhang <i>et al.</i> (2014)	1.384560	(1.1341154-1.6903105)
Wang <i>et al.</i> (2014)	1.309388	(1.0558735-1.6237718)
Feng <i>et al.</i> (2017)	1.328905	(1.0731231-1.6456532)
Combined	1.320050	(1.0708865-1.6271875)
BA vs. AA	Romain <i>et al.</i> (1999)	1.106631 (0.9993051-1.2254829) Random
	Ahomadegbe <i>et al.</i> (2000)	1.115426 (1.0057140-1.2371070)
	Ryan <i>et al.</i> (2001)	1.123842 (1.0113208-1.2488818)
	Hamajima <i>et al.</i> (2002)	1.139215 (1.0284778-1.2618757)
	Hamajima <i>et al.</i> (2002)	1.132178 (1.0193869-1.2574497)
	Hamajima <i>et al.</i> (2002)	1.133800 (1.0212653-1.2587351)
	Hiraki <i>et al.</i> (2003)	1.131726 (1.0186899-1.2573041)
	Huang <i>et al.</i> (2003)	1.136576 (1.0244304-1.2609981)
	Hishida <i>et al.</i> (2004)	1.114550 (1.0033197-1.2381121)
	Li(a) <i>et al.</i> (2004)	1.111378 (1.0010409-1.2338771)
	Li(b) <i>et al.</i> (2004)	1.114141 (1.0007142-1.2404241)
	Niwa(a) <i>et al.</i> (2004)	1.115610 (1.0010546-1.2432748)
	Hu <i>et al.</i> (2005)	1.122248 (1.0094269-1.2476787)
	Niwa(b) <i>et al.</i> (2005)	1.133906 (1.0212670-1.2589688)
	Pfeifer <i>et al.</i> (2005)	1.143752 (1.0347936-1.2641829)
	Choi <i>et al.</i> (2006)	1.117569 (1.0064924-1.2409034)
	Ge <i>et al.</i> (2006)	1.118427 (1.0050888-1.2445460)
	Ge <i>et al.</i> (2006)	1.128405 (1.0140483-1.2556573)
	Zheng <i>et al.</i> (2006)	1.123902 (1.0088218-1.2521090)
	Chen <i>et al.</i> (2008)	1.116457 (1.0055597-1.2395855)
	Li(c) <i>et al.</i> (2008)	1.125180 (1.0112145-1.2519893)

	Zheng <i>et al.</i> (2008)	1.127993	(1.0122669-1.2569482)
	Deo Feo <i>et al.</i> (2009)	1.131305	(1.01891540-1.256092)
	Kang <i>et al.</i> (2009)	1.094806	(0.9453852-1.2051811)
	Misra <i>et al.</i> (2009)	1.136959	(1.0248612-1.2613169)
	Lee <i>et al.</i> (2010)	1.128753	(1.0158259-1.2542344)
	Shirai <i>et al.</i> (2010)	1.112129	(1.0005869-1.2361055)
	Arfaoui <i>et al.</i> (2010)	1.128081	(1.0138044-1.2552380)
	Mittal <i>et al.</i> (2011)	1.117390	(1.0052334-1.2420594)
	Craveiro <i>et al.</i> (2012)	1.126159	(1.0133621-1.2515121)
	Sun <i>et al.</i> (2012)	1.131763	(1.0189650-1.2570463)
	Umar <i>et al.</i> (2012)	1.113547	(1.0022472-1.2372072)
	Zhou <i>et al.</i> (2012)	1.112337	(1.0015877-1.2353322)
	Zhang <i>et al.</i> (2014)	1.130211	(1.0172521-1.2557129)
	Wang <i>et al.</i> (2014)	1.112925	(1.0013776-1.2368977)
	Feng <i>et al.</i> (2017)	1.117607	(1.0055333-1.2421712)
	Combined	1.122900	(1.0124720-1.2453718)
BB+BA vs. AA			Random
	Romain <i>et al.</i> (1999)	1.137691	(1.0313668-1.2549757)
	Ahomadegbe <i>et al.</i> (2000)	1.144760	(1.0369698-1.2637535)
	Ryan <i>et al.</i> (2001)	1.157872	(1.0473412-1.2800682)
	Hamajima <i>et al.</i> (2002)	1.167436	(1.0584582-1.2876343)
	Hamajima <i>et al.</i> (2002)	1.160302	(1.0494526-1.2828590)
	Hamajima <i>et al.</i> (2002)	1.161420	(1.0507138-1.2837900)
	Hiraki <i>et al.</i> (2003)	1.159823	(1.0487431-1.2826670)
	Huang <i>et al.</i> (2003)	1.163557	(1.0529857-1.2857395)
	Hishida <i>et al.</i> (2004)	1.142271	(1.0333188-1.2627111)
	Li(a) <i>et al.</i> (2004)	1.143728	(1.0342451-1.2647996)
	Li(b) <i>et al.</i> (2004)	1.145781	(1.0329837-1.2708955)
	Niwa(a) <i>et al.</i> (2004)	1.144593	(1.0318558-1.2696481)
	Hu <i>et al.</i> (2005)	1.146866	(1.0365896-1.2688736)
	Niwa(b) <i>et al.</i> (2005)	1.159329	(1.0482337-1.2821976)
	Pfeifer <i>et al.</i> (2005)	1.177307	(1.0732897-1.2914060)
	Choi <i>et al.</i> (2006)	1.148775	(1.0391396-1.2699768)

	Ge <i>et al.</i> (2006)	1.148268	(1.0367036-1.2718384)
	Ge <i>et al.</i> (2006)	1.156936	(1.0446044-1.2813469)
	Zheng <i>et al.</i> (2006)	1.152702	(1.0396528-1.2780446)
	Chen <i>et al.</i> (2008)	1.148139	(1.0385279-1.2693180)
	Li(c) <i>et al.</i> (2008)	1.155061	(1.0430828-1.2790595)
	Zheng <i>et al.</i> (2008)	1.144066	(1.0320406-1.2682507)
	Deo Feo <i>et al.</i> (2009)	1.157241	(1.0464940-1.2797089)
	Kang <i>et al.</i> (2009)	1.125273	(1.0262575-1.2338406)
	Misra <i>et al.</i> (2009)	1.164561	(1.0541711-1.2865114)
	Lee <i>et al.</i> (2010)	1.153768	(1.0426797-1.2766911)
	Shirai <i>et al.</i> (2010)	1.141204	(1.0315313-1.2625375)
	Arfaoui <i>et al.</i> (2010)	1.157273	(1.0450821-1.2815067)
	Mittal <i>et al.</i> (2011)	1.150345	(1.0394986-1.2730113)
	Craveiro <i>et al.</i> (2012)	1.155567	(1.0447082-1.2781895)
	Sun <i>et al.</i> (2012)	1.163913	(1.0537320-1.2856148)
	Umar <i>et al.</i> (2012)	1.144549	(1.0345836-1.2662033)
	Zhou <i>et al.</i> (2012)	1.139914	(1.0316197-1.2595774)
	Zhang <i>et al.</i> (2014)	1.166127	(1.0564353-1.2872078)
	Wang <i>et al.</i> (2014)	1.142446	(1.0326366-1.2639317)
	Feng <i>et al.</i> (2017)	1.148600	(1.0380493-1.2709239)
	Combined	1.152058	(1.0435261-1.2718780)
BB vs. BA+AA			Random
		1.280292	(1.0402069-1.5757894)
		1.271044	(1.0339199-1.5625511)
		1.303375	(1.0669432-1.5921984)
		1.268349	(1.0288452-1.5636075)
		1.265541	(1.0260426-1.5609418)
		1.262319	(1.0234557-1.5569305)
		1.265281	(1.0254469-1.5612091)
		1.262941	(1.0222231-1.5603449)
		1.256862	(1.0183030-1.5513074)
		1.295471	(1.0545678-1.5914063)
		1.288746	(1.0424550-1.5932254)

Niwa(a) <i>et al.</i> (2004)	1.262680	(1.0157177-1.5696899)
Hu <i>et al.</i> (2005)	1.242432	(1.0097862-1.5286763)
Niwa(b) <i>et al.</i> (2005)	1.244930	(1.013824-1.5287175)
Pfeifer <i>et al.</i> (2005)	1.316514	(1.0750323-1.6122388)
Choi <i>et al.</i> (2006)	1.284109	(1.0445638-1.5785881)
Ge <i>et al.</i> (2006)	1.274597	(1.0314537-1.5750570)
Ge <i>et al.</i> (2006)	1.268475	(1.0252775-1.5693581)
Zheng <i>et al.</i> (2006)	1.268545	(1.0236333-1.5720526)
Chen <i>et al.</i> (2008)	1.287632	(1.0480676-1.5819544)
Li(c) <i>et al.</i> (2008)	1.279418	(1.0356594-1.5805490)
Zheng <i>et al.</i> (2008)	1.219571	(1.0345848-1.4376339)
Deo Feo <i>et al.</i> (2009)	1.255708	(1.0191657-1.5471506)
Kang <i>et al.</i> (2009)	1.259387	(1.0209192-1.5535556)
Misra <i>et al.</i> (2009)	1.267725	(1.0262104-1.5660799)
Lee <i>et al.</i> (2010)	1.256608	(1.0167701-1.5530203)
Shirai <i>et al.</i> (2010)	1.263744	(1.0211021-1.5640445)
Arfaoui <i>et al.</i> (2010)	1.274572	(1.0304883-1.5764707)
Mittal <i>et al.</i> (2011)	1.290407	(1.0535577-1.5805021)
Craveiro <i>et al.</i> (2012)	1.276300	(1.0352232-1.5735163)
Sun <i>et al.</i> (2012)	1.304202	(1.0631860-1.5998540)
Umar <i>et al.</i> (2012)	1.284534	(1.0419721-1.5835621)
Zhou <i>et al.</i> (2012)	1.252978	(1.0185923-1.5412984)
Zhang <i>et al.</i> (2014)	1.332216	(1.0945079-1.6215501)
Wang <i>et al.</i> (2014)	1.267262	(1.0263388-1.5647396)
Feng <i>et al.</i> (2017)	1.284721	(1.0423905-1.5833875)
Combined	1.273473	(1.0375487-1.5630421)

Supplementary table 4. *P* values of the Egger's test for *TP73 G4C14-A4T14* polymorphism.

Polymorphisms	Subgroup	Egger's test P > t
rs2273953	Overall	0.232
	Caucasian	0.533
	Asian	0.961
	Breast cancer	0.419
	Colorectal cancer	0.117
	SCCHN	0.765
	Cervical cancer	0.646
	Esophageal cancer	0.748
	Gastric cancer	0.739
	Lung cancer	0.202
	P-B	0.584
	H-B	0.322
	HWE(Y)	0.315
	HWE(N)	0.682




Fig.S1

Meta-analysis of the association between *TP73 G4C14-A4T14* polymorphism and breast cancer risk.




**B VS A****BB VS AA****BA VS AA****BB+BA VS AA****BB VS BA+AA**

Fig.S2

Meta-analysis of the association between *TP73 G4C14-A4T14* polymorphism and esophageal cancer risk.







Fig.S3



Meta-analysis of the association between *TP73 G4C14-A4T14* polymorphism and lung cancer risk.



B VS A

BB VS AA

BA VS AA



BB+BA VS AA

BB VS BA+AA

Fig.S4

Meta-analysis of the association between *TP73 G4C14-A4T14* polymorphism and squamous cell carcinoma of the head and neck cancer risk.




Fig.S5

Meta-analysis of the association between *TP73 G4C14-A4T14* polymorphism and cancer risks, stratification by ethnicity.





Fig.S6

Meta-analysis of the association between *TP73 G4C14-A4T14* polymorphism and cancer risks, stratification by source of control.





Fig.S7

Meta-analysis of the association between *TP73 G4C14-A4T14* polymorphism and cancer risks, stratification by whether conform to HWE.




Fig.S8

Begg's funnel plot for publication bias test for TP73 G4C14-A4T14 polymorphism (B vs. A), stratification by cancer type. The x-axis is log (OR), and the y-axis is natural logarithm of OR. The horizontal line in the figure represents the overall estimated log (OR). The two diagonal lines indicate the pseudo 95% confidence limits of the effect estimate.




Fig.6

Fig. S9 Sensitivity Analysis of Overall ORs Co-Efficients for TP73 G4C14-A4T14 polymorphism (GC vs. AT). Results were calculated by omitting each study in turn. The two ends of the dotted lines represent the 95% CIs.




Fig. S10 In-silico analysis the relative expression of p73 in cancer tissue and normal tissue using TCGA database.

BRCA: Breast invasive carcinoma; CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma; COAD: Colon adenocarcinoma; ESCA: Esophageal carcinoma; HNSC: Head and Neck squamous cell carcinoma; LUAD: Lung adenocarcinoma; LUSC: Lung squamous cell carcinoma; OV: Ovarian serous; PRAD: Prostate adenocarcinoma; READ: Rectum adenocarcinoma; SKCM: Skin Cutaneous Melanoma; STAD: Stomach adenocarcinoma.